Mediwound Ltd
NASDAQ:MDWD

Watchlist Manager
Mediwound Ltd Logo
Mediwound Ltd
NASDAQ:MDWD
Watchlist
Price: 16.48 USD -1.67% Market Closed
Market Cap: 177.8m USD
Have any thoughts about
Mediwound Ltd?
Write Note

Mediwound Ltd
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mediwound Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Mediwound Ltd
NASDAQ:MDWD
Revenue
$20.1m
CAGR 3-Years
-7%
CAGR 5-Years
-3%
CAGR 10-Years
72%
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Revenue
$16.3B
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
-2%
Sol Gel Technologies Ltd
NASDAQ:SLGL
Revenue
$11.7m
CAGR 3-Years
-2%
CAGR 5-Years
-9%
CAGR 10-Years
N/A
I
InterCure Ltd
TASE:INCR
Revenue
â‚Ş355.6m
CAGR 3-Years
76%
CAGR 5-Years
N/A
CAGR 10-Years
45%
S
Seach Medical Group Ltd
TASE:SEMG
Revenue
â‚Ş162.4m
CAGR 3-Years
61%
CAGR 5-Years
66%
CAGR 10-Years
64%
R
Rekah Pharmaceutical Industry Ltd
TASE:REKA
Revenue
â‚Ş324.4m
CAGR 3-Years
6%
CAGR 5-Years
11%
CAGR 10-Years
2%
No Stocks Found

Mediwound Ltd
Glance View

Market Cap
177.8m USD
Industry
Pharmaceuticals

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.

MDWD Intrinsic Value
10.47 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

What is Mediwound Ltd's Revenue?
Revenue
20.1m USD

Based on the financial report for Jun 30, 2024, Mediwound Ltd's Revenue amounts to 20.1m USD.

What is Mediwound Ltd's Revenue growth rate?
Revenue CAGR 10Y
72%

Over the last year, the Revenue growth was -22%. The average annual Revenue growth rates for Mediwound Ltd have been -7% over the past three years , -3% over the past five years , and 72% over the past ten years .

Back to Top